Antitumor Necrosis Factor Treatment for Pediatric Inflammatory Bowel Disease
Antitumor Necrosis Factor Treatment for Pediatric Inflammatory Bowel Disease
About this item
Full title
Author / Creator
Publisher
Oxford, UK: Oxford University Press
Journal title
Language
English
Formats
Publication information
Publisher
Oxford, UK: Oxford University Press
Subjects
More information
Scope and Contents
Contents
Infliximab, adalimumab, and certolizumab are monoclonal antibodies against tumor necrosis factor-α (TNFα), a proinflammatory cytokine with an increased expression in the inflamed tissues of inflammatory bowel disease (IBD) patients. Currently, infliximab is the only anti-TNF drug that has been approved for use in refractory pediatric Crohn's diseas...
Alternative Titles
Full title
Antitumor Necrosis Factor Treatment for Pediatric Inflammatory Bowel Disease
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1000407451
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1000407451
Other Identifiers
ISSN
1078-0998
E-ISSN
1536-4844
DOI
10.1002/ibd.21871
